Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
The U.S. Food and Drug Administration (FDA) agreed to review Merck’s application to add relapsed or refractory primary mediastinal large B-cell ... Read more
Adding the investigational treatment polatuzumab vedotin to a therapy of Bendeka (bendamustine) and Rituxan (rituximab) made patients with relapsed or refractory ... Read more
The European Commission has approved Novartis’ Tasigna (nilotinib) for the treatment of children with a specific type of chronic myeloid leukemia ... Read more
The U.S. Food and Drug Administration (FDA) has approved Roche’s Gazyva (obinutuzumab) in combination with chemotherapy as a first-line treatment for ... Read more
Takeda Pharmaceutical will present new data on Adcetris (brentuximab vedotin) as first-line therapy for advanced Hodgkin’s lymphoma at the 59th American Society ... Read more
European regulators have endorsed the use of Takeda‘s Adcetris (brentuximab vedotin) to treat a specific type of cutaneous T-cell lymphoma (CTCL). ... Read more
Novartis continues the process of making Kymriah (tisagenlecleucel) commercially available outside the U.S., now by applying with the European Medicines Agency ... Read more
Novartis has asked U.S. regulators to expand their approval of Kymriah (tisagenlecleucel) to include the treatment of adults with relapsed or ... Read more
